Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 3/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598991 | 0.80 | GPR183 (0.74) | GPR183L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL16598994 | 0.80 | GPR183 (0.74) | GPR183L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL10737402 | 0.80 | ACHE (0.52) | ACHETDP1GPR183MEN1KMT2A | |
| SCHEMBL10731939 | 0.79 | ACHE (0.50) | ACHETDP1MEN1KMT2A | |
| SCHEMBL10901880 | 0.78 | GPR183 (0.56) | GPR183L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL10901877 | 0.78 | GPR183 (0.56) | GPR183L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL6023907 | 0.78 | DHCR7 (0.48) | ABCB1GAAMAPK1MEN1KMT2A | |
| SCHEMBL10900566 | 0.78 | EBP (0.72) | GPR183L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL10900561 | 0.78 | EBP (0.72) | GPR183L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL10902157 | 0.77 | GPR183 (0.55) | GPR183GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | HTT, PARK7, NQO1 | ACHE 233/4885TDP1 310/4885GPR183 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.